Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prostate-specific antigen or PSA. Facts and probabilities]

L Boccon-Gibod1

  • 1Clinique Urologique, Hôpital Bichat, Paris.

Presse Medicale (Paris, France : 1983)
|October 28, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malformations, genetic abnormalities, and Wilms tumor.

Pediatric blood & cancer·2013
Same author

[Prostate cancer, androgenic suppression and associated conditions. Practical refinement by a panel of multidisciplinary experts for patient integral management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2012
Same author

[New perspectives in prostate cancer management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2010
Same author

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

[First line indications for hormonal therapy in prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2010
Same author

[AFU 2008 congress: Summary of the main communications about prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2009

Prostate-specific antigen (PSA) is crucial for monitoring prostate cancer treatment and detecting recurrence. While useful, PSA levels require interpretation alongside patient age and prostate volume for accurate diagnosis.

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Context:

  • Prostate-specific antigen (PSA) is an organ-specific marker vital for managing prostate diseases.
  • Elevated PSA levels indicate prostate gland abnormalities, including infectious, dystrophic, or cancerous processes.

Purpose:

  • To evaluate the utility of PSA assays in diagnosing and monitoring prostate cancer.
  • To discuss the interpretation of PSA levels in various clinical scenarios, including post-treatment follow-up and early diagnosis.

Summary:

  • PSA is the most effective marker for assessing the efficacy of prostate cancer treatment.
  • Post-radical prostatectomy, undetectable PSA (<0.1 ng/ml) at 6 weeks suggests successful treatment, while its persistence or reappearance indicates recurrence.
  • Decreasing PSA levels during hormone therapy for metastatic cancer signify treatment effectiveness but not a cure.

Related Experiment Videos

Impact:

  • PSA monitoring is essential for detecting prostate cancer recurrence and evaluating treatment response.
  • Interpreting PSA requires consideration of patient age and prostate volume, though a direct linear relationship is not established.
  • Further research into circulating tumor cells may enhance cancer staging and assessment.